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SERUM LEVELS OF RESISTIN AND INTERLEUKIN-17 ARE ASSOCIATED
WITH INCREASED CARTILAGE DEFECTS AND BONE MARROW
LESIONS IN PATIENTS WITH KNEE SYMPTOMATIC OSTEOARTHRITIS
K. Wang y, J. Xu y, J. Cai y, S. Zheng y, X. Yang y, C. Ding z,y. yDept. of
Rheumatology and Immunology, First Afﬁliated Hosp. of Anhui Med.
Univ., Hefei, China; zMenzies Inst. of Med. Res., Univ. of Tasmania,
Hobart, Australia
Purpose: To investigate cross-sectional associations between serum
levels of resistin and interleukin-17 and cartilage defects and bone
marrow lesions in patients with knee symptomatic osteoarthritis
(OA).
Methods: 194 randomly-selected patients with knee symptomatic OA
(mean 55.4 years, range 34 to 74, 87% females) were included in Anhui
Osteoarthritis (AHOA) Study. Knee cartilage defects and bone marrow
lesions were determined at medial and lateral tibial, femoral and
patellar sites using T2-weighted fat-suppressed fast spin echo MRI.
Serum resistin and IL-17 levels were measured using ELISA.
Results: Serum resistin was positively associated with cartilage defects
at lateral femoral (OR: 1.23, 95%CI 1.12 to 1.35), lateral tibial (OR: 1.14,
95%CI 1.04 to 1.24) and medial tibial (OR: 1.13, 95%CI 1.03 to 1.23) sites
after adjustment for covariates. The signiﬁcant associations were also
present with bone marrow lesions at lateral femoral (OR: 1.19, 95%CI
1.09 to 1.30) and tibial sites (OR: 1.13, 95%CI 1.02 to 1.24) after adjust-
ment for covariates. All these associations remained signiﬁcant after
further adjustment for IL-17. In patients with highest quartiles of hs-CRP
(> 2.45 pg/ml), IL-17 was signiﬁcantly associated with total cartilage
defect score (r¼0.267, p¼0.001) and cartilage defects at nearly all sites
(except for medial tibial) after adjustment for covariates. These sig-
niﬁcant associations decreased in magnitude and became non sig-
niﬁcant at medial femoral, lateral tibial and patellar sites after furtheradjustment for resistin. Similarly, IL-17 was signiﬁcantly associated
with BMLs at lateral and medial femoral sites after adjustment for
covariates, and the association at lateral femoral site became non sig-
niﬁcant after further adjustment for resistin.
Conclusions: Serum levels of resistin are independently and con-
sistently associated with cartilage defects and BMLs in patients with
knee OA. In addition, the associations of serum IL-17 with cartilage
defects and BMLs in patients with a higher inﬂammatory status are
largely mediated by resistin suggesting resistin may play a key role in
cartilage loss and bone abnormalities in patients with knee OA.
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PPARDELTA PROMOTES THE PROGRESSION OF POST-TRAUMATIC
OSTEOARTHRITIS
A. Ratneswaran y, I. Welch y, S.B. Golub z,x, A.J. Fosang z,x, F. Beier y,k.
yDept. of Physiology and Pharmacology, Western Univ., London, ON,
Canada; zDept. of Paediatrics, Univ. of Melbourne, Melbourne, Australia;
xMurdoch Children's Res. Inst., Melbourne, Australia; kChildren's
Hlth.Res. Inst., London, ON, Canada
Purpose: Osteoarthritis is a chronic degenerative joint disorder, char-
acterized by articular cartilage degeneration, subchondral bone thick-
ening, osteophyte formation, and synovial hyperplasia. The human
burden of this disease inﬂuences both the independence and quality of
life of those afﬂicted. Currently there are no pharmacological treat-
ments available to delay or reverse disease progression, and the lack of
available treatments can be attributed due to our incomplete under-
standing of the molecular mechanisms underlying disease initiation
and progression.
Recent ﬁndings from our laboratory indicate that activation of the
nuclear receptor PPARdelta induces the expression of enzymes involved
in proteoglycan breakdown, prompting us to speculate whether
inhibition of PPARdelta could be a viable target for OA treatment.
We aimed to characterize the role of PPARdelta in OA in order to
determinewhether activation of PPARdeltawould correlatewith an OA-
like phenotype and whether the inhibition of this nuclear receptor
could affect OA progression. We hypothesize that inhibition of PPAR-
delta will slow the progression of OA in animal models.
Methods: Primary mouse chondrocytes and cartilage explants were
treated with a pharmacological PPARdelta agonist (GW501516) to
evaluate changes in gene expression (qPCR), aggrecan breakdown (Dye-
binding assay;Western Blotting) and histology (Safranin-O, immuno-
histochemistry) consistent with OA development. Microarrays are
conducted on primary mouse chondrocytes treated with GW501516 to
elucidate information on direct targets of this nuclear receptor. In order
to examine the role of PPARdelta in-vivo, cartilage-speciﬁc knockout
mice and wild-type littermate controls were subjected to destabiliza-
tion of medial meniscus surgery (DMM) at 20 weeks of age. 8 weeks
post-surgery mice were compared through classical histological and
biochemical measures of OA progression including Safranin-O staining
with OARSI scoring, immunohistochemistry for cartilage matrix
breakdown products, and picrosirius red staining for collagen ﬁber
structure and orientation.
Results: In vitro, PPARdelta agonism (by GW501516) results in the
upregulation of expression of proteases implicated in cartilage degen-
eration (including MMPs and ADAMTS genes). Activation of PPARdelta
also results in proteoglycan breakdown in the cartilage matrix in an
explant culture system, as well as increased aggrecan breakdown
products in the medium. Western blots of medium and guanidine
extracts depict speciﬁc aggrecan neoepitopes present in the medium
and guanidine extracts. Microarray results have identiﬁed targets of
PPARdelta, such as those involved in lipid oxidation and transport.
Mice with cartilage-speciﬁc deletion of PPARdelta do not demonstrate
any abnormalities in skeletal growth or development, but show sig-
niﬁcant chondroprotection in comparison to wild-type littermate con-
trols after surgical induction of OA. OARSI scoring and
immunohistochemistry conﬁrm strong protection of mutant mice
against cartilage matrix breakdown, and decreased breakdown prod-
ucts in the cartilage of PPARdelta knockout mice.
Conclusions: This study provides strong evidence for catabolic roles
of endogenous PPARdelta in post-traumatic OA and suggests that
pharmacological inhibition of PPARdelta is a promising therapeutic
strategy.
